drugset
drugset / Trial / NCT05461235

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

NCT05461235 ↗

Phase 2 Unknown 1 enrolled China Medical University, China
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.

Timeline

Start
2022-07-15
Primary completion
2025-07-15
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 3 mg/kg Intravenous
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject DC-Cell Unknown 1e+06 cells/kg Other
Subject NK cell Cell therapy 1e+06 cells/kg Other
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous
Subject Nivolumab Monoclonal antibody 240 mg Intravenous
Subject Pembrolizumab Monoclonal antibody 2 mg/kg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Subject Sintilimab Monoclonal antibody 200 mg Intravenous
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Subject Toripalimab Monoclonal antibody 3 mg/kg Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

digestive system cancer